KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $19.7 million.

  • Travere Therapeutics' Change in Accured Expenses rose 72846.93% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year increase of 18946.46%. This contributed to the annual value of -$31.1 million for FY2024, which is 22543.31% down from last year.
  • Latest data reveals that Travere Therapeutics reported Change in Accured Expenses of $19.7 million as of Q3 2025, which was up 72846.93% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Change in Accured Expenses peaked at $19.7 million during Q3 2025, and registered a low of -$24.8 million during Q1 2024.
  • In the last 5 years, Travere Therapeutics' Change in Accured Expenses had a median value of $2.4 million in 2024 and averaged $2.3 million.
  • In the last 5 years, Travere Therapeutics' Change in Accured Expenses surged by 860529.41% in 2021 and then tumbled by 113754.76% in 2024.
  • Over the past 5 years, Travere Therapeutics' Change in Accured Expenses (Quarter) stood at $10.4 million in 2021, then crashed by 40.9% to $6.2 million in 2022, then soared by 180.17% to $17.3 million in 2023, then tumbled by 55.29% to $7.7 million in 2024, then soared by 154.77% to $19.7 million in 2025.
  • Its last three reported values are $19.7 million in Q3 2025, $1.3 million for Q2 2025, and -$9.5 million during Q1 2025.